Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30910209 | 0.81 | — | — | |
| SCHEMBL31393523 | 0.79 | — | — | |
| SCHEMBL29179914 | 0.75 | MAPK13 (0.39) | — | |
| SCHEMBL23563020 | 0.74 | KDM4E (0.33) | HTR1AHTR7HTR6 | |
| SCHEMBL31704421 | 0.74 | KDM4E (0.33) | HTR1AHTR7HTR6 | |
| SCHEMBL31424394 | 0.74 | HTR1A (0.34) | HTR1AHTR7HTR6 | |
| SCHEMBL23562918 | 0.74 | — | — | |
| SCHEMBL23563025 | 0.71 | ELANE (0.38) | — | |
| SCHEMBL31704315 | 0.71 | ELANE (0.38) | — | |
| SCHEMBL21404374 | 0.70 | CREBBP (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217647-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250127792-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-24 | — | — | US | disclosed |
| WO-2025049976-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-12186324-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-07 | — | — | US | disclosed |
| CN-112165944-B | Imidazopiperazine inhibitors of transcriptional activator proteins | 德州大学系统董事会 | 2024-04-09 | — | — | CN | disclosed |
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-12 | — | — | US | disclosed |
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-12 | — | — | US | disclosed |
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-13 | — | — | US | disclosed |
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-13 | — | — | US | disclosed |
| WO-2021126804-A1 | INDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| CN-112165944-A | Imidazopiperazine inhibitors of transcriptional activator proteins | 德州大学系统董事会 | 2021-01-01 | — | — | CN | disclosed |
| WO-2019191667-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-10-03 | — | — | US | disclosed |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, CREBBP, RBBP7 | HTR1A 4334/4885HTR7 3443/4885HTR6 3951/4885 |
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | HTR1A 4334/4885HTR7 3443/4885HTR6 3951/4885 |
| US-20250127792-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | HTR1A 4334/4885HTR7 3443/4885HTR6 3951/4885 |
| US-12186324-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, CREBBP, RBBP7 | HTR1A 4334/4885HTR7 3443/4885HTR6 3951/4885 |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | HTR1A 4334/4885HTR7 3443/4885HTR6 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.